Sanofi Consumer Healthcare India Ltd vs Shree Ganesh Biotech India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Sanofi Consumer Healthcare India Ltd is ₹ 4802 as of 18 May 15:30 . The P/E Ratio of Sanofi Consumer Healthcare India Ltd changed from 62.6 on December 2024 to 62.6 on December 2024 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Shree Ganesh Biotech India Ltd changed from 740.6 on March 2021 to 0 on December 2024 . This represents a CAGR of -100.00% over 7 years The Market Cap of Sanofi Consumer Healthcare India Ltd changed from ₹ 11347 crore on December 2024 to ₹ 11347 crore on December 2024 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Shree Ganesh Biotech India Ltd changed from ₹ 236.18 crore on March 2021 to ₹ 0 crore on December 2024 . This represents a CAGR of -100.00% over 7 years The revenue of Sanofi Consumer Healthcare India Ltd for the Mar '26 is ₹ 0 crore as compare to the Jun '26 revenue of ₹ 234.8 crore. This represent the decline of -100% The revenue of Shree Ganesh Biotech India Ltd for the Mar '26 is ₹ 2.4 crore as compare to the Jun '26 revenue of ₹ 0 crore. This represent the growth of 9.2233718E16% The ebitda of Sanofi Consumer Healthcare India Ltd for the Mar '26 is ₹ 0 crore as compare to the Jun '26 ebitda of ₹ 94.4 crore. This represent the decline of -100% The ebitda of Shree Ganesh Biotech India Ltd for the Mar '26 is ₹ -0.15 crore as compare to the Jun '26 ebitda of ₹ 0 crore. This represent the decline of -9.2233718E16% The net profit of Sanofi Consumer Healthcare India Ltd changed from ₹ 62.7 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The net profit of Shree Ganesh Biotech India Ltd changed from ₹ 0.24 crore to ₹ -0.15 crore over 9 quarters. This represents a CAGR of NaN% The Dividend Payout of Sanofi Consumer Healthcare India Ltd changed from 6.06 % on December 2023 to 69.89 % on December 2024 . This represents a CAGR of 239.60% over 2 yearsThe Dividend Payout of Shree Ganesh Biotech India Ltd changed from 0 % on March 2021 to 0 % on December 2024 . This represents a CAGR of 0.0% over 7 years .

About Sanofi Consumer Healthcare India Ltd

Sanofi Consumer Healthcare India Limited was incorporated on May 10, 2023, as part of Sanofi's global strategy to establish a standalone Consumer Healthcare business.
This strategic move resulted in the demerger of the Consumer Healthcare business from Sanofi India Limited (SIL) into the Company through a Scheme of Arrangement, thereby creating a distinct legal entity.
The Scheme of Arrangement, which was sanctioned by the National Company Law Tribunal, Mumbai (NCLT) enabled the seamless transfer and vesting of all assets, liabilities, and operations of SIL to the Company. Pursuant to the Scheme becoming effective, the Consumer Healthcare Division (CHC) business of Sanofi India Limited (SIL) got demerged into the Company as a going concern through the Scheme of Arrangement and became effective from June 1, 2024.

About Shree Ganesh Biotech India Ltd

Shree Ganesh Biotech India Limited was incorporated on September 2, 1982, as 'S.P. Commercial Co. Limited' with the Registrar of Companies, West Bengal.
The Company got the Certificate of Commencement of Business on September 14, 1982.
The Company was incorporated with an object to carry on the business of builders, Contractors and to deal in property and also to do investment and finance business. In 2010, pursuant to a Scheme of Amalgamation, Shree Ganesh Bio-Tech (India) Private Limited was merged with S.P. Commercial Co. Limited pursuant to the order of the Hon'ble High at Calcutta dated February 15, 2010.
The entire business of Shree Ganesh Bio-Tech (India) Private Limited consisting of trading and distribution of seeds were transferred to S.P. Commercial Co. Limited.
Subsequently, Shree Ganesh Bio-Tech (India) Private Limited was dissolved pursuant to the said Scheme of Amalgamation and the name of the Company was changed to Shree Ganesh Bio-Tech (India) Limited.

FAQs for the comparison of Sanofi Consumer Healthcare India Ltd and Shree Ganesh Biotech India Ltd

Which company has a larger market capitalization, Sanofi Consumer Healthcare India Ltd or Shree Ganesh Biotech India Ltd?

Market cap of Sanofi Consumer Healthcare India Ltd is 11,059 Cr while Market cap of Shree Ganesh Biotech India Ltd is 24 Cr

What are the key factors driving the stock performance of Sanofi Consumer Healthcare India Ltd and Shree Ganesh Biotech India Ltd?

The stock performance of Sanofi Consumer Healthcare India Ltd and Shree Ganesh Biotech India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanofi Consumer Healthcare India Ltd and Shree Ganesh Biotech India Ltd?

As of May 18, 2026, the Sanofi Consumer Healthcare India Ltd stock price is INR ₹4802.25. On the other hand, Shree Ganesh Biotech India Ltd stock price is INR ₹0.61.

How do dividend payouts of Sanofi Consumer Healthcare India Ltd and Shree Ganesh Biotech India Ltd compare?

To compare the dividend payouts of Sanofi Consumer Healthcare India Ltd and Shree Ganesh Biotech India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.